

Title (en)
MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR

Title (de)
SPEZIFISCH AN GITR BINDENDER MONOKLONALER ANTIKÖRPER

Title (fr)
ANTICORPS MONOCLONAL SE LIANT SPÉCIFIQUEMENT À GITR

Publication
EP 3964525 A4 20221228 (EN)

Application
EP 20794288 A 20200423

Priority

- RU 2019112296 A 20190423
- RU 2020050080 W 20200423

Abstract (en)
[origin: EP3964525A2] The present invention relates to biotechnology, in particular to antibodies or antigen-binding fragments thereof, and to use thereof. More particularly, the present invention relates to monoclonal antibodies that specifically bind to GITR. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with GITR.

IPC 8 full level
C07K 16/24 (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01); **C12N 5/10** (2006.01); **C12N 15/13** (2006.01); **C12N 15/63** (2006.01); **C12P 21/08** (2006.01)

CPC (source: CN EP IL KR RU US)
A61K 39/395 (2013.01 - IL RU); **A61K 47/68** (2017.08 - IL RU); **A61P 35/00** (2018.01 - CN EP IL KR RU US); **C07K 16/2878** (2013.01 - CN EP IL KR RU US); **C07K 16/46** (2013.01 - IL RU US); **A61K 2039/505** (2013.01 - CN EP IL KR); **C07K 2317/21** (2013.01 - EP US); **C07K 2317/22** (2013.01 - EP US); **C07K 2317/24** (2013.01 - CN EP IL US); **C07K 2317/33** (2013.01 - EP US); **C07K 2317/55** (2013.01 - CN EP IL KR US); **C07K 2317/56** (2013.01 - CN IL); **C07K 2317/565** (2013.01 - CN IL US); **C07K 2317/73** (2013.01 - EP); **C07K 2317/732** (2013.01 - CN EP IL KR US); **C07K 2317/734** (2013.01 - CN IL); **C07K 2317/75** (2013.01 - EP); **C07K 2317/76** (2013.01 - CN IL US); **C07K 2317/92** (2013.01 - CN EP IL KR); **C07K 2317/94** (2013.01 - CN EP IL US)

Citation (search report)

- [Y] US 2018044430 A1 20180215 - CHIU MARK [US], et al
- [Y] US 2015353637 A1 20151210 - WANG CHANGYU [US], et al
- [Y] WO 2018005950 A1 20180104 - FIVE PRIME THERAPEUTICS INC [US], et al
- [Y] US 2018355051 A1 20181213 - GONZALEZ ANA M [US], et al
- See also references of WO 2020218951A2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
EP 3964525 A2 20220309; EP 3964525 A4 20221228; AR 118763 A1 20211027; AU 2020261207 A1 20211223; BR 112021021281 A2 20220308; CA 3137822 A1 20201029; CL 2021002792 A1 20220624; CN 110903392 A 20200324; CN 110903392 B 20240213; CO 2021014153 A2 20211029; EA 202192907 A1 20220125; IL 287531 A 20211201; JO P20210286 A1 20230130; JP 2022532991 A 20220721; KR 20220010501 A 20220125; MA 54969 A1 20220831; MA 55390 A1 20220531; MA 55390 B1 20221031; MX 2021012962 A 20211215; PE 20220144 A1 20220127; RU 2734432 C1 20201016; TW 202100554 A 20210101; TW I803718 B 20230601; US 2022213209 A1 20220707; UY 38672 A 20201030; WO 2020218951 A2 20201029; WO 2020218951 A3 20201224; ZA 202109374 B 20221221

DOCDB simple family (application)
EP 20794288 A 20200423; AR P200101146 A 20200423; AU 2020261207 A 20200423; BR 112021021281 A 20200423; CA 3137822 A 20200423; CL 2021002792 A 20211022; CN 201911222245 A 20191203; CO 2021014153 A 20211022; EA 202192907 A 20200423; IL 28753121 A 20211024; JO P20210286 A 20200423; JP 2021563239 A 20200423; KR 20217038209 A 20200423; MA 54969 A 20200423; MA 55390 A 20200630; MX 2021012962 A 20200423; PE 2021001765 A 20200423; RU 2019112296 A 20190423; RU 2020050080 W 20200423; TW 108144110 A 20191203; US 202017605933 A 20200423; UY 38672 A 20200422; ZA 202109374 A 20211122